It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
How to choose the right membrane protein mimetic for your research
What are the considerations when deciding upon which option is best to present a target membrane protein?
In this article Riccardo Cavalieri and Steven Harborne discuss the subject and present examples of the current state of play within the field.
Introduction
Membrane proteins present numerous technical challenges to experimental research. They are expressed at low levels, are often highly dynamic, and can become unstable when removed from the native lipid bilayer. The cell lipid environment, in fact, plays a central role in maintaining their structural integrity and functional dynamics, and its disruption can lead to misfolding, aggregation, or loss of activity. As a result, careful consideration of the membrane mimetic system to be chosen is required from the earliest stages of experimental design.
Choosing a membrane mimetic for membrane protein purification requires balancing biological relevance against experimental tractability. If a membrane protein cannot be successfully extracted from its native membrane and maintained in a soluble, functional state, other factors become largely irrelevant. The choice of membrane mimetic is thus often dictated by the necessity to enable efficient extraction of the target protein, and provide sufficient stability for purification, storage, and subsequent characterisation, rather than by considerations on preserving a “native–like” environment.
What is a membrane protein mimetic?
Numerous membrane mimetics with distinct physicochemical properties are available to scientists for the study of membrane proteins. They can be grouped in four broad categories: detergents, polymer lipid particles (PLP) such as styrene maleic acid lipid particles (SMALPs), protein-based nanodiscs, and liposomes.
Detergents
Detergents are the most established and versatile approach, with extensive precedent in the literature; however, they strip away most native lipids and the harsher among them can destabilize some fragile membrane proteins.
SMALPs
In contrast, polymer based nanodiscs such as SMALPs enable direct extraction of proteins from the membrane together with their surrounding native lipid environment, better preserving physiologically relevant interactions. Despite this advantage, purification can be more challenging, the resulting particles are often heterogeneous, and the methodology is less firmly established.
Nanodiscs
Nanodiscs provide a controlled lipid bilayer environment with defined particle size, making them particularly attractive for structural studies such as cryo-electron microscopy (cryo-EM), although they require prior solubilization in detergent and optimization of lipid composition and reconstitution conditions.
Liposomes
Finally, liposomes most closely resemble biological membranes. The possibility to create electrochemical gradients across the membrane makes them the gold standard for functional assays. They are also widely used in mechanistic studies and antibody generation. Nonetheless, their preparation is complex and requires that the sample has previously been purified in detergents. Liposomes can also be fragile, exhibiting limited stability during storage and freeze–thaw cycles before starting to leak.
Membrane mimetics are not just passive surfactants that keep the protein in solution, but active physical environments that reshape the conformational behaviour of membrane proteins. Rising evidence from cryo-EM structures, functional assays, biophysical measurements, computational studies, and comparative analyses across detergents, protein nanodiscs, polymers, and liposomes points to the fact that the choice of membrane mimetic fundamentally determines which regions of a protein’s conformational space are accessible or suppressed.
The current state of play
The first point of note is that retention of endogenous lipids does not equate to preservation of native membrane physics. Nanodiscs (polymer or MSP‑based) co‑extract or reconstitute lipids, yet systematically alter their physical properties: lipid packing, lateral pressure profiles, and bilayer elasticity. Whilst polymers that directly extract proteins from the membrane (e.g. SMA, DIBMA, etc) are often thought of as native-like environment, native lipids can coexist with non-native mechanical constraints, leading to conformational biases.
Secondly, stability (especially as measured by thermal shift assays) is often considered a good proxy for correct, physiologically relevant folding and sample quality. While a good stability of the sample is certainly an indicator of tractability for structural studies, recent data on the neurotensin receptor and ABC transporters ABCB10, ABCB25 and LmrA, show that detergents such as LMNG and GDN, as well as small MSP nanodiscs (especially the most used MSP1D1 based), increase stability, homogeneity, and cryo-EM tractability of the protein samples, but do so at the expenses of the conformational ensemble sampled. In both GPCRs and ABC transporters, this stabilisation correlates with reduced ligand efficacy, altered basal activity, and dampened regulatory responses.
Third, recent publications in the literature collectively show that single structures are insufficient descriptors of membrane protein function. High resolution cryo-EM structures frequently capture only the most stabilised state of the protein, and investigating the protein in multiple membrane mimetic environment might be necessary to gain a more complete understanding of its conformational flexibility. An example of this approach has been a paper by Hoffman and colleagues on the ABC transporter MsbA, whose structure was solved in 12 different membrane mimetics (detergents and nanodiscs).
So, what’s the best fit for different applications?
A distinction between structural resolution and functional or biophysical interrogation thus seems to be required when approaching a new membrane protein: no single mimetic optimally serves both objectives, and an exhaustive approach will often need to study the protein of interest in multiple environments.
For single particle cryo-EM applications, success appears to correlate with mimetics that impose strong constraints (high stability and rigidity, low population heterogeneity), such as rigid detergents (LMNG, GDN) or small nanodiscs. These environments are optimal to yield high resolution structures but bias the system towards deep, narrow free energy minima. For proteins with strong lipid dependence (GPCRs, transporters), this often means enrichment of preactivated or artificially stabilised states. Larger nanodiscs (≥18 nm) partially alleviate these effects by reducing lateral pressure, albeit at the cost of increased heterogeneity and potentially lower resolution. Comparative multi environment approaches can provide complementary structural snapshots that collectively represent a broader conformational landscape.
For functional and biophysical assays (e.g. SPR, MST, DSF, etc), the logic is inverted. Mimetics that pre-stabilise basal states or suppress conformational heterogeneity reduce the dynamic range of measurable response. Larger nanodiscs, liposomes, or fast exchange detergents (e.g. DM/DDM) perform better because they preserve the energetic balance required for ligands or substrates to redistribute populations across states. Crucially, assays that measure changes rather than absolute values are the most sensitive to distortions introduced by the choice of membrane mimetic.
Conclusion: the value of a balanced approach
In conclusion, mimetic choice is not simply about preserving compositional similarity to native membranes, or maximising stability of the sample. While the ideal system would preserve the native membrane environment for downstream analyses, it must also allow the protein to be extracted, stabilised, purified, and handled under experimental conditions. If the target protein proves tractable and the choice of membrane mimetics is opened to the scientist, careful consideration is necessary to avoid artificially biasing the protein towards a narrower conformational landscape. Moreover, due attention is to be given to the desired downstream applications for the sample and to selecting approaches that are most appropriate for addressing the research question of interest.
Bibliography
Bower etal., 2026 –Protein Science Stabilization versus flexibility: Detergent‑dependent trade‑offs in neurotensin receptor 1 GPCR ensembles → Established the ΔG_conf vs ΔG_ligand partitioning and showed that high stability (LMNG) can suppress ligand‑induced stabilisation.
NouelBarreto etal., 2025 –FEBS Letters ABC transporter activity is affected by the size of lipid nanodiscs → Demonstrated that small MSP nanodiscs bias basal activity and dampen regulatory responses, while large nanodiscs approximate liposomes functionally.
Arcario etal., 2025 –BBA Biomembranes Examining the thermotropic properties of large circularized nanodiscs → Quantified how increasing nanodisc diameter progressively recovers bulk bilayer properties, but never fully matches liposomes for complex lipid mixtures.
RealHernandez &Levental, 2023 –Biophysical Journal Lipid packing is disrupted in copolymeric nanodiscs compared with intact membranes → Showed that polymer nanodiscs alter lipid headgroup packing and lateralpressure, even when native lipids are retained.
Johansen etal., 2023 –Biochimie Travel light: Essential packing for membrane proteins with an active lifestyle → Provided the thermodynamic and kinetic framework linking detergency, conformational bias, ligand retention, lipid exchange, and carrier choice.
Hägg etal., 2026 –BBA – Biomembranes How receptor conformation depends on lipid nanodisc size: Adenosine A₂A receptor and implications for classA GPCR proteins → Demonstrated GPCR‑specific nanodisc‑size–dependent conformational bias
Fernandes & Zoonens, 2026 – Current Opinion in Structural Biology Trends in the use of amphipathic environments and future perspectives for determining the structure of membrane proteins by cryo‑EM → Positioned detergents, nanodiscs, polymers, Salipro, and emerging systems within cryo‑EM practice, explicitly emphasising environment‑dependent structural bias and the need for cross‑validation.
Harpole & Delemotte, 2018 – BBA – Biomembranes Conformational landscapes of membrane proteins delineated by enhanced sampling molecular dynamics simulations
Hoffman et al., 2025 – Structure The ABC transporter MsbA in a dozen environments